SUBSCRIBE
SUBSCRIBE
News   Business

Intercell AG (JOBS) Eyes FY Loss on Weak Vaccine Sales

November 9, 2009 | 
1 min read

Bookmark and Share

Reuters -- Austrian biotech company Intercell (ICEL.VI) scrapped its full-year profit target after third-quarter revenue for its Ixiaro vaccine against Japanese Encephalitis fell short of expectations.

Earnings
MORE ON THIS TOPIC
Financial Crisis Concept. Bankrupt Businessman Character Stand at Sinking Paper Ship Waving White Flag in Sea with scatter Dollar Bills and Coins Business Man Bankruptcy. Cartoon Vector Illustration
Layoffs
Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship
February 4, 2025
 · 
1 min read
 · 
Kate Goodwin
vial of vaccine for the vaccination plan against diseases in the China. Doctor with a vial with doses of the vaccine in front of the China flag
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
February 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
BMS, Turnstone, Charles River Axe Staff
February 4, 2025
 · 
119 min read
 · 
BioSpace Editorial Staff
Pictured: Regeneron logo on a light brown building
Earnings
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac